Citigroup Maintains Buy on Tandem Diabetes Care, Lowers Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Joanne Wuensch maintains a Buy rating on Tandem Diabetes Care (NASDAQ:TNDM) but lowers the price target from $55 to $45.
June 05, 2023 | 10:25 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup maintains Buy rating on Tandem Diabetes Care (TNDM) but lowers price target from $55 to $45.
The news of Citigroup maintaining a Buy rating on Tandem Diabetes Care (TNDM) is positive for the stock. However, the lowering of the price target from $55 to $45 may create some uncertainty among investors, potentially offsetting the positive impact of the Buy rating. Therefore, the short-term impact on TNDM's stock price is expected to be neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100